CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite this, the effects of these drug combinations on reducing cell counts and increasing cell death within BP-CML cell lines and, more importantly, within the primitive CD34+ population of myeloid BP-CML patient samples, to a greater degree than in healthy samples, provides a strong rationale for further clinical investigation.